1. Home
  2. CYTK vs OMAB Comparison

CYTK vs OMAB Comparison

Compare CYTK & OMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CYTK
  • OMAB
  • Stock Information
  • Founded
  • CYTK 1997
  • OMAB 1998
  • Country
  • CYTK United States
  • OMAB Mexico
  • Employees
  • CYTK N/A
  • OMAB N/A
  • Industry
  • CYTK Biotechnology: Pharmaceutical Preparations
  • OMAB Aerospace
  • Sector
  • CYTK Health Care
  • OMAB Consumer Discretionary
  • Exchange
  • CYTK Nasdaq
  • OMAB Nasdaq
  • Market Cap
  • CYTK 4.6B
  • OMAB 5.4B
  • IPO Year
  • CYTK 2004
  • OMAB 2006
  • Fundamental
  • Price
  • CYTK $53.01
  • OMAB $105.42
  • Analyst Decision
  • CYTK Buy
  • OMAB Buy
  • Analyst Count
  • CYTK 15
  • OMAB 4
  • Target Price
  • CYTK $75.57
  • OMAB $102.50
  • AVG Volume (30 Days)
  • CYTK 2.6M
  • OMAB 80.8K
  • Earning Date
  • CYTK 11-05-2025
  • OMAB 10-24-2025
  • Dividend Yield
  • CYTK N/A
  • OMAB 3.80%
  • EPS Growth
  • CYTK N/A
  • OMAB 3.19
  • EPS
  • CYTK N/A
  • OMAB 0.71
  • Revenue
  • CYTK $85,738,000.00
  • OMAB $834,652,401.00
  • Revenue This Year
  • CYTK $330.96
  • OMAB $4.41
  • Revenue Next Year
  • CYTK $73.41
  • OMAB $14.65
  • P/E Ratio
  • CYTK N/A
  • OMAB $18.08
  • Revenue Growth
  • CYTK 2635.74
  • OMAB 5.84
  • 52 Week Low
  • CYTK $29.31
  • OMAB $62.06
  • 52 Week High
  • CYTK $59.39
  • OMAB $116.26
  • Technical
  • Relative Strength Index (RSI)
  • CYTK 77.96
  • OMAB 50.24
  • Support Level
  • CYTK $35.22
  • OMAB $100.50
  • Resistance Level
  • CYTK $50.22
  • OMAB $105.60
  • Average True Range (ATR)
  • CYTK 2.29
  • OMAB 2.80
  • MACD
  • CYTK 1.64
  • OMAB -0.17
  • Stochastic Oscillator
  • CYTK 94.73
  • OMAB 49.15

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

About OMAB Grupo Aeroportuario del Centro Norte S.A.B. de C.V. ADS

Grupo Aeroportuario del Centro Norte SAB de CV operates airports in the central region of Mexico. The airport is in Monterrey, which serves nearly half of the company's total passengers. In addition, the company manages two hotels and one industrial park. Its reportable segments include its airports, the Terminal 2 NH Collection Hotel, the Hilton Garden Inn Hotel and the OMA-VYNMSA Industrial Park, individually, and information about its holding company and other companies is combined in the Others.

Share on Social Networks: